Gastric Cancer Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | EMD Serono, Sumitomo Pharma, LintonPharm, Eli Lilly and Company, Janssen, Ellipses, Bayer, GlaxoSmithKline, LianBio

As per DelveInsight, the Gastric Cancer Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Gastric Cancer in the 7MM. Already prescribed products along with the launch of emerging therapies will also drive the market growth.

DelveInsight's "Gastric Cancer Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Gastric Cancer Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Gastric Cancer therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Gastric Cancer treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Gastric Cancer: An Overview
Gastric (stomach) cancer occurs when cancer cells form in the lining of the stomach. There are 5 layers in the stomach wall: mucosa, submucosal, muscularis propria, subserosa and serosa. The location of the tumor and the layers involved play an important role in determining the stage (extent) of the cancer. This can affect a person's treatment options and prognosis. As the cancer grows from the mucosa into deeper layers, the stage becomes more advanced and demands extensive treatment.

Most of the gastric cancers (about 95-90%) are adenocarcinoma. Gastric adenocarcinoma is of two pathological variants, intestinal and diffuse. The intestinal type is the end result of an inflammatory process that progresses from chronic gastritis to atrophic gastritis and finally to intestinal metaplasia and dysplasia. This type is more common among elderly men, unlike the diffuse type, which is more prevalent among women and in individuals under the age of 50. HER2 is an important biomarker that is proven to be an independent prognostic factor. Based on this, GC is of two types: HER2+ Gastric cancer and HER2- Gastric cancer.

The clinical practice guidelines for gastric cancer are geography-specific, to accommodate the differences in drugs/diagnostics availability, affordability, and government support across geographies: US (NCCN), EU (ESMO), and Japan (JSGA). However, a general algorithm exists for the treatment. Surgery is the primary treatment option for patients with localized gastric cancer. Chemotherapy is the recommended treatment option for the management of unresectable, locally advanced, recurrent, or metastatic gastric cancer. There are several types of chemotherapeutic agents such as ADC (antibody-drug conjugates), immunotherapies, vaccines, and a variety of targeted therapies like anti-HER2+, anti-PD-L1 agents, etc.

Gastric carcinoma (GC) is the fifth most common malignancy worldwide (1,089,103 new cases per year in 2020) and is the third leading cause of cancer deaths (768,793 deaths annually) of all malignancies worldwide. The disease becomes symptomatic in an advanced stage.

Gastric Cancer Market Key Facts
• According to the American Cancer Society's estimates for gastric cancer in the United States for 2022, there are about 26,380 new cases of stomach cancer (15,900 in men and 10,480 in women) and about 11,090 deaths from this type of cancer (6,690 men and 4,400 women).
• Although the incidence of gastric cancer is decreasing in Western countries, including the US, there is an increasing incidence of gastroesophageal junction (GEJ) cancer. This is majorly attributable to several potential risk factors such as diet (high in salty and smoked foods) reflux disease, body weight, obesity, H.pylori infection, smoking, etc.
• According to the recent GLOBOCAN data, in 2020 the estimated number of cases of Gastric cancer in the US, EU4, the UK, and Japan, are 26,259; 50,383; 138,470; and 478,508 cases, respectively.
• According to the American Cancer Society's estimates for gastric cancer in the United States for 2022, there are about 26,380 new cases of stomach cancer (15,900 in men and 10,480 in women) and About 11,090 deaths from this type of cancer (6,690 men and 4,400 women).
• According to Global Cancer Observatory, in developed countries, gastric cancer is 2.2 times more likely to be diagnosed in males than females. In developing countries, this ratio is 1.83.
• Among the 7MM, Japan (136,592 cases in 2021) has the highest, and the UK (6,682 cases in 2021) has the lowest number of incident cases of Gastric Cancer.
• Among the EU4 and the UK countries, Italy leads the pack with an incidence rate of 24.7/100,000, followed by Spain (23.1), Germany (21.6), France (17.0), and the UK (14.2).

Discover How Gastric Cancer Market will Grow by 2032:
https://www.delveinsight.com/report-store/gastric-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Gastric Cancer Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Gastric Cancer therapies in the market. It also provides a detailed assessment of the Gastric Cancer market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the market trend for each marketed Gastric Cancer drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Gastric Cancer Epidemiology
The epidemiology section covers detailed insights into the historical, and current Gastric Cancer patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Gastric Cancer Epidemiology Segmented as -
• Total Diagnosed Incidence Cases of Gastric Cancer in the 7MM [2019-2032]
• Stage-specific Cases of Gastric Cancer in the 7MM [2019-2032]
• Gender-specific Cases of Gastric Cancer in the 7MM [2019-2032]
• Total Treatable Cases of Gastric Cancer in the 7MM [2019-2032]
• Biomarker-specific Cases of Gastric Cancer in the 7MM [2019-2032]

Get Key Insights Into the Evolving Gastric Cancer Epidemiology Trends:
https://www.delveinsight.com/report-store/gastric-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Gastric Cancer Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastric Cancer market or expected to be launched during the study period. The analysis covers the market share by Gastric Cancer drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Gastric Cancer Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities:
https://www.delveinsight.com/sample-request/gastric-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Gastric Cancer Therapeutics Assessment
The emerging drugs for Gastric Cancer shall impact the market size significantly, considering the pipeline with a variety of therapeutic classes in the periphery. At present, there are a decent number of biologics and drugs under investigation for the treatment of Gastric Cancer. Key players such as Amgen, Zymworks, Astellas, Merck, and others are some of the major players that are going to boost the market dynamics in the coming years. Currently, Innovent Biologics is leading the therapeutics market with its Gastric Cancer drug candidates in the most advanced stage of clinical development.

Leading Companies in the Gastric Cancer Therapeutics Market Include
Hutchison Medipharma Limited, EMD Serono, Sumitomo Pharma, Jiangsu HengRui Medicine Co., Ltd., LintonPharm Co.,Ltd., Rapa Therapeutics LLC, Jiangsu HengRui Medicine Co., Ltd., Eli Lilly and Company, Janssen Pharmaceutical K.K., Hoffmann-La Roche, Novartis, Genentech, Exelixis, Bristol-Myers Squibb, Pieris Pharmaceuticals, Inc., Pfizer, Leap Therapeutics, CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Merck Sharp & Dohme LLC, Amgen, Hanmi Pharmaceutical, Taiho Oncology, Inc., Merck KGaA, Shanghai Henlius Biotech, Shanghai Henlius Biotech, LianBio LLC, Chengdu Kanghong Biotech, Merck Sharp & Dohme LLC, AB Science, Maxinovel, Shanghai Miracogen Inc., Shanghai Miracogen Inc., GlaxoSmithKline, Hoffmann-La Roche, Merck Sharp & Dohme, Bayer, Hutchison Medipharma Limited, and many others.

Emerging and Marketed Gastric Cancer Therapies Covered in the Report Include
• Bemarituzumab: Amgen
• HLX10: Henlix Biotech
• IBI308: Innovent Biologics
• Lenvatinib: Eisai Pharma/Merck
• Pamiparib: BeiGene
• TRANSCENTA, TST001: TRANSCENTA
• Zolbetuximab: Astellas
And Many More

Learn More About the Emerging Therapies & Key Companies in the Gastric Cancer Therapeutics Market:
https://www.delveinsight.com/sample-request/gastric-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Gastric Cancer Competitive Intelligence Analysis
4. Gastric Cancer Market Overview at a Glance
5. Gastric Cancer Background and Overview
6. Gastric Cancer Patient Journey
7. Gastric Cancer Epidemiology and Patient Population
8. Gastric Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Gastric Cancer Unmet Needs
10. Key Endpoints of Gastric Cancer Treatment
11. Gastric Cancer Marketed Products
12. Gastric Cancer Emerging Therapies
13. Gastric Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Gastric Cancer Market Outlook (7 major markets)
16. Gastric Cancer Access and Reimbursement Overview
17. KOL Views on the Gastric Cancer Market.
18. Gastric Cancer Market Drivers
19. Gastric Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings:
https://www.delveinsight.com/sample-request/gastric-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight -
Bowen's Disease Market
https://www.delveinsight.com/report-store/bowens-disease-market

Cartilage Diseases Market
https://www.delveinsight.com/report-store/cartilage-diseases-market

Charcot-Marie-Tooth Disease Market
https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market

Cryptococcosis Market
https://www.delveinsight.com/report-store/cryptococcosis-market

Dental Lasers Market
https://www.delveinsight.com/report-store/dental-lasers-market

Diabetes Market
https://www.delveinsight.com/report-store/diabetes-market

Diverticulitis Market
https://www.delveinsight.com/report-store/diverticulitis-market

Down Syndrome Market
https://www.delveinsight.com/report-store/down-syndrome-market

Endocarditis Market
https://www.delveinsight.com/report-store/endocarditis-market

Extracorporeal Circulation System Market
https://www.delveinsight.com/report-store/extracorporeal-circulation-system-market

Gastro Intestinal Bleeding Market
https://www.delveinsight.com/report-store/gastro-intestinal-bleeding-market

Gene Therapy for Ocular Rare Disease Market
https://www.delveinsight.com/report-store/gene-therapy-for-ocular-rare-disease-market

Germ Cell Tumor Market
https://www.delveinsight.com/report-store/germ-cell-tumor-market

India Healthcare Outlook
https://www.delveinsight.com/report-store/india-healthcare-outlook-report

Insulin Glargine Biosimilar Insight
https://www.delveinsight.com/report-store/insulin-glargine-biosimilar-insight

Listeriosis Market
https://www.delveinsight.com/report-store/listeriosis-market

Liver Angiosarcoma Market
https://www.delveinsight.com/report-store/liver-angiosarcoma-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.